Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 7 | 2025 | 459 | 3.030 |
Why?
|
| E-Selectin | 3 | 2016 | 27 | 1.110 |
Why?
|
| SEER Program | 1 | 2024 | 47 | 0.920 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 27 | 0.920 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 18 | 0.890 |
Why?
|
| Medicare | 1 | 2024 | 124 | 0.890 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2021 | 15 | 0.720 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 25 | 0.660 |
Why?
|
| Aptamers, Nucleotide | 2 | 2015 | 13 | 0.600 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 82 | 0.500 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 162 | 0.450 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 325 | 0.420 |
Why?
|
| Female | 8 | 2025 | 15156 | 0.390 |
Why?
|
| Antigens, CD | 2 | 2023 | 140 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 465 | 0.380 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 1319 | 0.330 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 679 | 0.320 |
Why?
|
| Membrane Proteins | 2 | 2023 | 484 | 0.300 |
Why?
|
| Mice | 5 | 2025 | 4654 | 0.290 |
Why?
|
| Mice, Inbred BALB C | 3 | 2025 | 276 | 0.290 |
Why?
|
| Humans | 10 | 2025 | 28097 | 0.280 |
Why?
|
| Animals | 6 | 2025 | 10423 | 0.260 |
Why?
|
| Cell Adhesion | 2 | 2016 | 138 | 0.240 |
Why?
|
| Histone Deacetylases | 1 | 2025 | 26 | 0.240 |
Why?
|
| Mastectomy | 1 | 2024 | 21 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 33 | 0.230 |
Why?
|
| Prognosis | 2 | 2024 | 803 | 0.230 |
Why?
|
| Repressor Proteins | 1 | 2025 | 118 | 0.230 |
Why?
|
| Biopsy, Needle | 1 | 2023 | 48 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 1 | 2023 | 68 | 0.210 |
Why?
|
| Neoplasms | 2 | 2023 | 809 | 0.210 |
Why?
|
| Exosomes | 1 | 2025 | 96 | 0.210 |
Why?
|
| Endocytosis | 1 | 2022 | 89 | 0.190 |
Why?
|
| ErbB Receptors | 1 | 2022 | 100 | 0.190 |
Why?
|
| Hormones | 1 | 2021 | 43 | 0.180 |
Why?
|
| Breast | 1 | 2021 | 52 | 0.170 |
Why?
|
| Disease Progression | 2 | 2025 | 473 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 478 | 0.160 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 2021 | 0.160 |
Why?
|
| Risk Factors | 1 | 2024 | 2081 | 0.160 |
Why?
|
| Cell Movement | 2 | 2022 | 373 | 0.150 |
Why?
|
| United States | 1 | 2024 | 2146 | 0.150 |
Why?
|
| Retrospective Studies | 1 | 2024 | 2546 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2022 | 806 | 0.140 |
Why?
|
| Aged | 2 | 2024 | 5400 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 105 | 0.130 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 31 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 163 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 165 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 315 | 0.120 |
Why?
|
| Complement C5a | 1 | 2015 | 5 | 0.120 |
Why?
|
| Complement C3a | 1 | 2015 | 6 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.120 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 26 | 0.120 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 27 | 0.120 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 65 | 0.120 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2015 | 5 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 269 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 34 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 25 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 85 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 43 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 224 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 123 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 356 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 607 | 0.110 |
Why?
|
| Kidney | 1 | 2015 | 286 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2016 | 848 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2015 | 612 | 0.100 |
Why?
|
| Cytokines | 1 | 2015 | 447 | 0.100 |
Why?
|
| Apoptosis | 1 | 2016 | 775 | 0.100 |
Why?
|
| Liver | 1 | 2015 | 440 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 352 | 0.090 |
Why?
|
| Biomarkers | 1 | 2015 | 765 | 0.090 |
Why?
|
| Male | 3 | 2023 | 13491 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2025 | 118 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2025 | 331 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Tetraspanins | 1 | 2023 | 54 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 29 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 405 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 115 | 0.050 |
Why?
|
| Melanoma | 1 | 2023 | 141 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 178 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 277 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 56 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 44 | 0.040 |
Why?
|
| Survival Rate | 1 | 2018 | 430 | 0.030 |
Why?
|
| Middle Aged | 1 | 2025 | 7138 | 0.030 |
Why?
|